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Introduction {#sec005}
============

The association between migraine and narcolepsy has been evaluated in several hospital-based studies and still remains controversial \[[@pone.0189231.ref001]--[@pone.0189231.ref003]\]. These studies adopted case-control cross-sectional study designs with relatively small sample sizes, which could not allow us to firmly establish a causal relationship between migraine and narcolepsy, or suggest a mechanism that could explain such relationship. Furthermore, as almost one-third of patients become symptomatic before reaching the age of 15, there is an increasing level of attention given on the development of narcolepsy early in life \[[@pone.0189231.ref004]\]. Unfortunately, whether migraine is associated with increased risk of narcolepsy in children has not been explored in a large-scale longitudinal study.

Migraine has been considered a disturbance in the brain of the subcortical aminergic sensory modulatory systems, in addition to hypothalamic, thalamic and brainstem structures \[[@pone.0189231.ref005],[@pone.0189231.ref006]\]. Hypothalamic orexinergic neurons actively enhance waking promoting monoaminergic and cholinergic hypothalamic and brainstem neural networks \[[@pone.0189231.ref007]\]. The destruction of orexinergic system results in narcolepsy as well as altered pain processing including migraine \[[@pone.0189231.ref008]\]. Given that migraine may share with narcolepsy in distinct brain areas especially in hypothalamus and neurotransmitter systems or both, we hypothesize that migraine can be linked to narcolepsy, particularly in children whose been observed with relatively high incidence. Therefore, we conduct a retrospective population-based cohort study using the Taiwan National Health Insurance Research Database (NHIRD) to investigate whether migraine is associated with an elevated risk of developing narcolepsy in children less than 18 years of age.

Materials and methods {#sec006}
=====================

Data source {#sec007}
-----------

A population-based longitudinal study was designed for this investigation. Our data source was the Taiwan National Health Insurance Research Database (NHIRD), which is a large computerized medical claims-based database released by the National Health Insurance Administration (NHIA) and maintained by the National Health Research Institutes (NHRI) for research purposes.

The NHI is a compulsory health insurance program in the country, offering a comprehensive benefits package. It currently has a national coverage of over 99% and is contracted with 97% of the health services providers in Taiwan. Thus, the NHIRD compiles an ample set of medical-claims records from preventive screening to medication history that is valuable for studying the health and service utilization of the entire population. For this study, we specifically used NHIRD registry files for children (aged \<18 years) who are enrolled under the NHI program. From 1996 to 2012, a random, national-representative sample of enrolled children less than 18 years old were selected (n = 2,861,326). Outpatient, inpatient and medication records of these selected children were obtained for subsequent analysis. All diagnoses and disease definitions in this study were specified using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes.

All data from the NHIRD has been electronically encrypted for confidentiality reasons. Before its public release, all data with personal identification information, including patient identification number, birth date, gender, physician identification number and physician specialty, are all encrypted so that subjects can never be purposefully traced. The design and protocol of this study has been approved by the Research Ethics Committee at the China Medical University Hospital (CRREC-103-048(CR-2)).

Study design & subject selection {#sec008}
--------------------------------

For our study (migraine) cohort, we identified children aged less than 18 years from the random, national-representative sample who have newly diagnosed migraine between 1997 and 2010 (n = 38,284). We included different types of migraine including migraine with aura (ICD-9-CM: 346.0x), migraine without aura (ICD-9-CM: 346.1x) and unspecified migraine (ICD-9-CM: 346.9x). For ascertainment of cases, any identified subject should have at least two ambulatory care and/or inpatient visits with migraine diagnosis during the study period. We excluded those diagnosed with headache (ICD-9-CM: 346.2x; n = 886), missing information regarding subject's sex and birthday, their date of narcolepsy diagnosis (n = 22,651), or those who had withdrawn from the NHI program before migraine diagnosis (n = 4,620) ([Fig 1](#pone.0189231.g001){ref-type="fig"}). A sum of 10,127 subjects resulted in the migraine cohort. For these children, their first date of migraine diagnosis became their index date of observation. In a similar manner, children without any migraine diagnosis from the random sample were identified during the same period of time to form the comparison (non-migraine) cohort. They were subsequently propensity-score-matched with the migraine children by age, sex, urbanization level, comorbidities, and index year at a 4:1 ratio (migraine: n = 8,923; non-migraine: n = 35,692). Analogous exclusion criteria were applied to the non-migraine cohort before matching.

![Subject selection flowchart.](pone.0189231.g001){#pone.0189231.g001}

Outcome variable {#sec009}
----------------

Our primary outcome was the occurrence of narcolepsy (ICD-9-CM: 347), defined as the initial outpatient visit or hospital admission for narcolepsy during the follow-up period. Both cohorts were followed up until December 31 of 2012, their withdrawal from the NHI program, or the incidence of narcolepsy.

Demographic and comorbidities profile {#sec010}
-------------------------------------

We considered baseline demographic variables including sex, age and urbanization level. Age was categorized into 3 groups: 0--5, 6--11 and 12--17 years old. For defining urbanization level of each subject's area of residence, we used townships within which subjects enrolled their insurance as reference; four levels of urbanization (1 highest to 4 lowest) were classified based on a score calculated by incorporating variables indicating population density (number of people per squared kilometer), population ratio of different educational levels, elderly, agricultural workers and the number of physicians per 100,000 people \[[@pone.0189231.ref009]\]. Baseline comorbidities that could potentially influence our outcome were also considered. They included schizophrenia and organic psychosis (ICD-9-CM: 293--295), affective psychoses (ICD-9-CM: 296), neurotic disorders (ICD-9-CM: 300), depression (ICD-9-CM: 311), learning disability and developmental delay (ICD-9-CM: 315), mental retardation (ICD-9-CM: 317--319), central nervous system (CNS) infection (ICD-9-CM: 320--326), cerebral palsy (ICD-9-CM: 342--344), cerebral vascular disorder (ICD-9-CM:430--438), head injury with skull fracture (ICD-9-CM: 800--804, 850--854, 959.99), vision problems (ICD-9-CM: 36x-37x) and insomnia (ICD-9-CM: 307.41, 307.42, 307.49, 780.50, 780.52, 780.55, 780.56, 780.59). Effect of any medication containing nonsteroidal anti-inflammatory drug (NSAID), ergotamine, acetaminophen, triptan, antiepileptic, antipsychotic, and sedative-hypnotic that was used in these children during the study period was also considered.

Statistical analysis {#sec011}
--------------------

In our descriptive analysis, continuous data was expressed as means with standard deviation (SD) and categorical data were expressed as percentages (%). We compared baseline characteristics between children with and without migraine using standardized mean difference (SMD). SMD of less than 0.2 SD is indicative of negligible effect size in means or proportions of a propensity-score matched sample \[[@pone.0189231.ref010]\]. Incidence density rates were calculated for each cohort based on their incident events of narcolepsy and were expressed as per 1,000 person-years. Using log-rank test, the statistical difference in the cumulative incidence of narcolepsy between migraine and non-migraine cohorts was tested, and the Kaplan-Meier method was used to plot the survival probability. Both univariate and multivariate Cox proportional hazards regression models were performed to estimate hazard ratios (HRs) and their 95% confidence intervals (CIs) for the development of narcolepsy in the study cohort compared to the matched comparison cohort. All statistical tests were performed at the two-tailed significance level of 0.05. Analyses were carried out using the SAS statistical software (version 9.4 for Windows; SAS Institute, Inc., Cary, NC, USA).

Results {#sec012}
=======

After propensity-score matching, we selected 8,923 children with migraine and 35,692 control children without migraine for analysis. [Table 1](#pone.0189231.t001){ref-type="table"} describes the baseline characteristics of these identified subjects according to their migraine status (yes or no). As expected, subjects from both cohorts exhibited homogeneous post-match distributions for age, sex, urbanization level and comorbidities. Mean age was 11.58±3.88 and 11.02±3.94 years for migraine and non-migraine children, respectively, with a SMD of 0.145. In terms of baseline comorbidities and concurrent medication use, proportions of schizophrenia and organic psychosis, affective psychoses, neurotic disorders, depression, learning disability and developmental delay, mental retardation, CNS infection, cerebral palsy, cerebral vascular disorder, head injury with skull fracture, vision problems, insomnia, use of NSAIDs, ergotamine, acetaminophen, triptans and sedative-hypnotics are similar in migraine and non-migraine subjects. Concomitant use of antiepileptics and antipsychotics, however, were found with considerable differences (SMD\>0.20). Thus, they were further adjusted for in the multivariate analyses. Among migraine children, most belonged to the unspecified migraine type (71.75%, n = 6,402). As a part of data exploration, we also found negligible SMD in the prevalence of other confounding conditions such as hyperactivity, infectious diseases of the upper respiratory tract, influenza and epilepsy between our matched children.

10.1371/journal.pone.0189231.t001

###### Descriptive profile of the matched study and comparison cohorts.
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  Variable                                                      Migraine       Standardized mean difference                   
  ------------------------------------------------------------- -------------- ------------------------------ ------- ------- -------
  **Follow time (mean, median) (years)**                        5.04 (4.53)    4.68 (4.01)                                    
  **Sex**                                                                                                                     0.061
      Girls                                                     20842          58.39                          4942    55.38   
      Boys                                                      14850          41.61                          3981    44.62   
  **Age (years)**                                                                                                             
      0--5                                                      4331           12.13                          763     8.55    
      6--11                                                     15730          44.07                          3818    42.79   
      12--17                                                    15631          43.79                          4341    48.66   
      Mean (SD[^a^](#t001fn002){ref-type="table-fn"}) (years)   11.02 (3.94)   11.58 (3.88)                   0.145           
  **Urbanization level**                                                                                                      0.001
      1 (highest)                                               10397          29.13                          2659    29.80   
      2                                                         11118          31.15                          2728    30.57   
      3                                                         6981           19.56                          1661    18.61   
      4 (lowest)                                                7196           20.16                          1875    21.01   
  **Comorbidities**                                                                                                           
      Schizophrenia and organic psychosis                       41             0.11                           14      0.16    0.011
      Affective psychoses                                       54             0.15                           22      0.25    0.021
      Neurotic disorders (anxiety)                              784            2.20                           210     2.35    0.011
      Depression                                                40             0.11                           13      0.15    0.009
      Learning disability and developmental delay               831            2.33                           260     2.91    0.037
      Mental retardation (intellectual disability)              264            0.74                           81      0.91    0.019
      CNS infection                                             347            0.97                           100     1.12    0.015
      Cerebral palsy                                            143            0.40                           45      0.50    0.015
      Cerebral vascular disorder                                159            0.45                           45      0.50    0.009
      Head injury with skull fracture                           1854           5.19                           513     5.75    0.024
      Vision problems                                           30417          85.22                          7195    80.63   0.122
      Insomnia                                                  759            2.13                           234     2.62    0.033
  **Concomitant medication use**                                                                                              
      NSAIDs                                                    34175          95.75                          8324    93.29   0.108
      Ergotamine                                                5475           15.34                          1418    15.89   0.015
      Acetaminophen                                             34619          96.99                          8414    94.3    0.132
      Triptans                                                  144            0.40                           15      0.17    0.044
      Antiepileptics                                            1062           2.98                           981     10.99   0.319
      Antipsychotics                                            4208           11.79                          1782    19.97   0.225
      Sedative-hypnotics                                        690            1.93                           414     4.64    0.152
  **Migraine Subtype**                                                                                                        
      Migraine with aura                                        .              .                              1049    11.76   
      Migraine without aura                                     .              .                              1869    20.95   
      Unspecified migraine                                      .              .                              6402    71.75   

Chi-Square Test

^a^ t-test

SD: standard deviation; CNS: central nervous system; NSAIDs: nonsteroidal anti-inflammatory drugs

A total of 13 subjects were newly diagnosed with narcolepsy during the follow-up period, with incidence rates of 0.1915 and 0.0278 per 1,000 person-years in the migraine and non-migraine cohorts, respectively. [Table 2](#pone.0189231.t002){ref-type="table"} displays results from univariate and multivariate Cox proportional hazards model analyses with the non-migraine group as the reference. Adjusted for the effects of sex, age, urbanization level, baseline comorbidities and concurrent medication use, a higher adjusted risk (aHR: 5.30, 95% CI: 1.61, 17.4, p = 0.006) of narcolepsy was observed in migraine children compared to non-migraine children. The Kaplan-Meier survival curve with log-rank test also showed higher cumulative incidence of narcolepsy in children with migraine (p = 0.0007) ([Fig 2](#pone.0189231.g002){ref-type="fig"}).

![Cumulative incidence of narcolepsy in children diagnosed with migraine versus children without migraine.\
(dotted line) Incidence of narcolepsy in children of the migraine cohort in the observation period. (solid line) Incidence of narcolepsy in children of the non-migraine (reference) cohort.](pone.0189231.g002){#pone.0189231.g002}
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###### Results from Cox proportional hazards model for the association between narcolepsy and migraine in pediatric subjects (hazard ratios and 95% confidence intervals).
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  -------------------------------------------------------------------------------------------------------------------------------------
  Variable                                           Narcolepsy\   Crude\*   Adjusted^†^                                       
                                                     (n = 13)                                                                  
  -------------------------------------------------- ------------- --------- --------------- ---------- ------ --------------- --------
  **Migraine**                                                                                                                 

      No                                             5             1.00      reference                  1.00   reference       

      Yes                                            8             6.75      (2.21--20.6)    0.0008     5.30   (1.61--17.38)   0.0060

  **Sex**                                                                                                                      

      Girls                                          6             1.00      reference                  1.00   reference       

      Boys                                           7             1.56      (0.52--4.64)    0.4236     1.51   (0.49--4.62)    0.4684

  **Age (years)**                                                                                                              

      0--5                                           0             \-        \-              \-         \-     \-              \-

      6--11                                          4             1.00      reference                  1.00   reference       

      12--17                                         9             3.21      (0.97--10.6)    0.0558     2.51   (0.72--8.76)    0.1496

  **Urbanization level**                                                                                                       

      1 (highest)                                    6             1.00      reference                  1.00   reference       

      2                                              1             0.16      (0.02--1.29)    0.0848     0.18   (0.02--1.53)    0.1163

      3                                              3             0.74      (0.19--2.97)    0.6728     0.93   (0.23--3.79)    0.9226

      4 (lowest)                                     3             0.71      (0.18--2.84)    0.6282     0.87   (0.21--3.61)    0.8523

  **Comorbidities**                                                                                                            

      Schizophrenia and organic psychosis            0             \-        \-              \-         \-     \-              \-

      Affective psychoses                            0             \-        \-              \-         \-     \-              \-

      Neurotic disorders (anxiety)                   3             16.81     (4.61--61.3)    \< .0001   8.33   (1.98--35.06)   0.0039

      Depression                                     0             \-        \-              \-         \-     \-              \-

      Learning disability and developmental delay    1             3.29      (0.43--25.3)    0.2521     2.76   (0.32--23.93)   0.3572

      Mental retardation (intellectual disability)   0             \-        \-              \-         \-     \-              \-

      CNS infection                                  0             \-        \-              \-         \-     \-              \-

      Cerebral palsy                                 0             \-        \-              \-         \-     \-              \-

      Cerebral vascular disorder                     0             \-        \-              \-         \-     \-              \-

      Head injury with skull fracture                1             1.57      (0.2--12.05)    0.6661     1.44   (0.18--11.59)   0.7325

      Vision problems                                12            2.23      (0.29--17.2)    0.4405     2.38   (0.30--18.95)   0.4130

      Insomnia                                       2             10.58     (2.33--48.1)    0.0022     5.13   (0.99--26.64)   0.0518

  **Concomitant medication use**                                                                                               

      NSAIDs                                         11            0.14      (0.03--0.63)    0.0109     0.27   (0.05--1.44)    0.1247

      Ergotamine                                     4             2.19      (0.67--7.12)    0.1926     3.29   (0.94--11.44)   0.0617

      Acetaminophen                                  12            0.19      (0.02--1.51)    0.117      0.46   (0.05--4.19)    0.4923

      Triptans                                       0             \-        \-              \-         \-     \-              \-

      Antiepileptics                                 3             5.85      (1.61--21.27)   0.0073     4.06   (0.99--16.61)   0.0511

      Antipsychotics                                 1             0.49      (0.06--3.79)    0.4959     0.32   (0.04--2.55)    0.2813
  -------------------------------------------------------------------------------------------------------------------------------------

NSAIDs--nonsteroidal anti-inflammatory drugs

Crude HR\* represented relative hazard ratio

Adjusted HR^†^ represented adjusted hazard ratio: jointly adjusted for migraine, gender, age, insurance premium, urbanization level, comorbidities and concomitant medications in Cox proportional hazards regression.

Stratified by sex, the incidence rates of narcolepsy in girls and boys with migraine were 0.1382 and 0.2492 per 1,000 person-years, respectively; higher than those in the control cohort (0.0285 and 0.0268 per 1,000 person-years) ([Table 3](#pone.0189231.t003){ref-type="table"}). In addition, migraine boys showed 6.68-fold (95% CI: 1.17, 38.1, p\<0.05) higher adjusted risk of developing narcolepsy than the non-migraine cohort. Also observed with a statistically elevated risk of narcolepsy were migraine children belonging to age group of 12--17 years old (aHR: 4.20, 95% CI: 1.05, 16.7, p\<0.05), those with listed comorbidities (aHR: 5.08, 95% CI: 1.56, 16.5, p\<0.01), non-users of triptans (aHR: 5.08, 95% CI: 1.56, 16.5, p\<0.01), or users of NSAIDs (aHR: 6.50, 95% CI: 1.81, 23.4, p\<0.01) and acetaminophen (aHR: 4.87, 95% CI: 1.46, 16.3, p\<0.01). Although regression models could not be analyzed for the use of antiepileptics or antipsychotics due to zero count in cells for controls, we observed that there was higher narcolepsy incidence in the migraine group compared to the non-migraine group: 3 events in cases vs. 0 event in controls who had concomitant antiepileptic use, and 1 event in cases vs. 0 event in controls who had concomitant antipsychotic use. Furthermore, among children without any concurrent antiepileptic or antipsychotic uptake, migraine children were observed with statistically higher risk of narcolepsy: aHR: 4.14, 95% CI: 1.16, 14.8, p\<0.05 and aHR: 4.88, 95% CI: 1.46--16.3, p\<0.01, respectively. Lastly, [Table 4](#pone.0189231.t004){ref-type="table"} gives the results of our sensitivity analysis with different migraine subtypes. The risk of narcolepsy is consistently higher in the migraine children when compared to non-migraine counterparts except for unspecified migraine: highest in migraine with aura (aHR: 9.03, 95% CI: 2.34, 34.8, p\<0.01), followed by migraine without aura (aHR: 5.76, 95% CI: 1.48, 22.5, p\<0.05).

10.1371/journal.pone.0189231.t003

###### Incidence rates, hazard ratios and confidence intervals of narcolepsy for children patients with and without migraine stratified by demographic attribute, comorbidity and concomitant medication.
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  Variables                        Migraine   Crude HR   Adjusted HR                                                                                     
  -------------------------------- ---------- ---------- ------------- --- ------- -------- ------------------------------------------------------------ -----------------------------------------------------------
  **Total**                        5          179729     0.0278        8   41771   0.1915   6.75 (2.21--20.6)[\*\*](#t003fn004){ref-type="table-fn"}     5.30 (1.61--17.38)[\*\*](#t003fn004){ref-type="table-fn"}
  **Sex**                                                                                                                                                
      Girls                        3          105086     0.0285        3   21704   0.1382   4.72 (0.95--23.4)                                            4.79 (0.91--25.09)
      Boys                         2          74644      0.0268        5   20067   0.2492   9.44 (1.83--48.7)[\*\*](#t003fn004){ref-type="table-fn"}     6.68 (1.17--38.05)[\*](#t003fn003){ref-type="table-fn"}
  **Age (years)**                                                                                                                                        
      0--5                         0          35653      0             0   6769    0        \-                                                           \-
      6--11                        1          97159      0.0103        3   22913   0.1309   12.58 (1.31--120.9)[\*](#t003fn004){ref-type="table-fn"}     10.59 (0.99--113.66)
      12--17                       4          46917      0.0853        5   12077   0.4140   4.83 (1.30--17.9)[\*](#t003fn004){ref-type="table-fn"}       4.20 (1.05--16.72)[\*](#t003fn004){ref-type="table-fn"}
  **Urbanization level**                                                                                                                                 
      1 (highest)                  3          50858      0.059         3   12751   0.2353   4.06 (0.82--20.1)                                            2.65 (0.48--14.77)
      2                            0          56128      0             1   12822   0.078    \-                                                           \-
      3                            0          35947      0             3   8013    0.3744   \-                                                           \-
      4 (lowest)                   2          36796      0.0544        1   8186    0.1222   2.02 (0.18--22.3)                                            2.27 (0.20--25.19)
  **Comorbidities**                                                                                                                                      
      No                           0          30406      0             0   9348    0        \-                                                           \-
      Yes                          5          149323     0.0335        8   32423   0.2467   7.09 (2.32--21.7)[\*\*\*](#t003fn005){ref-type="table-fn"}   5.08 (1.56--16.54)[\*\*](#t003fn004){ref-type="table-fn"}
  **Concomitant medication use**                                                                                                                         
      NSAIDs                                                                                                                                             
          No                       1          3171       0.3154        1   1128    0.8862   2.91 (0.18--46.6)                                            2.08 (0.12--36.85)
          Yes                      4          176558     0.0227        7   40643   0.1722   7.48 (2.19--25.6)[\*\*](#t003fn004){ref-type="table-fn"}     6.50 (1.81--23.38)[\*\*](#t003fn004){ref-type="table-fn"}
      Ergotamine                                                                                                                                         
          No                       5          146263     0.0342        4   34944   0.1145   3.36 (0.9--12.5)                                             3.20 (0.82--12.45)
          Yes                      0          33466      0             4   6827    0.5859   \-                                                           \-
      Acetaminophen                                                                                                                                      
          No                       0          1935       0             1   799     1.2522   \-                                                           \-
          Yes                      5          177794     0.0281        7   40973   0.1708   5.96 (1.89--18.8)[\*\*](#t003fn004){ref-type="table-fn"}     4.87 (1.46--16.26)[\*](#t003fn003){ref-type="table-fn"}
      Triptans                                                                                                                                           
          No                       5          178406     0.028         8   41673   0.192    6.73 (2.2--20.6)[\*\*\*](#t003fn005){ref-type="table-fn"}    5.08 (1.56--16.54)[\*\*](#t003fn004){ref-type="table-fn"}
          Yes                      0          1324       0             0   98      0        \-                                                           \-
      Antiepileptics                                                                                                                                     
          No                       5          172122     0.0290        5   36270   0.1379   4.63 (1.34--15.99)[\*](#t003fn003){ref-type="table-fn"}      4.14 (1.16--14.82)[\*](#t003fn003){ref-type="table-fn"}
          Yes                      0          7607       0             3   5501    0.5454   \-                                                           \-
      Antipsychotics                                                                                                                                     
          No                       5          154224     0.0324        7   32062   0.2183   6.59 (2.09--20.75)[\*\*](#t003fn004){ref-type="table-fn"}    4.88 (1.46--16.31)[\*\*](#t003fn004){ref-type="table-fn"}
          Yes                      0          25506      0             1   9709    0.1030   \-                                                           \-

Abbreviation: IR, incidence rates, per 1,000 person-years; HR, hazard ratio; CI, confidence interval

Adjusted HR: adjusted for migraine, sex, age, insurance premium, urbanization level, comorbidities and drug used in Cox proportional hazard regression.

\*:\<0.05

\*\*:\<0.01

\*\*\* p\<0.001

10.1371/journal.pone.0189231.t004

###### Incidence rates and hazard ratios of narcolepsy in different migraine subtypes.
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  Migraine type                        Event no.   Person-years   Incidence rate per 1000 person-years   Crude HR (95% CI)                                            Adjusted HR (95% CI)
  ------------------------------------ ----------- -------------- -------------------------------------- ------------------------------------------------------------ -----------------------------------------------------------
  **Migraine with aura (346.0x)**                                                                                                                                     
      No                               10          216430         0.05                                   1.00 (reference)                                             1.00 (reference)
      Yes                              3           5071           0.59                                   12.9 (3.55--46.9)[\*\*\*](#t004fn005){ref-type="table-fn"}   9.03 (2.34--34.82)[\*\*](#t004fn004){ref-type="table-fn"}
  **Migraine without aura (346.1x)**                                                                                                                                  
      No                               10          213679         0.05                                   1.00 (reference)                                             1.00 (reference)
      Yes                              3           7821           0.38                                   7.39 (2.03--28.9)[\*\*](#t004fn004){ref-type="table-fn"}     5.76 (1.48--22.45)[\*](#t004fn003){ref-type="table-fn"}
  **Unspecified migraine (346.9x)**                                                                                                                                   
      No                               8           190672         0.04                                   1.00 (reference)                                             1.00 (reference)
      Yes                              5           30828          0.16                                   3.88 (1.27--11.9)[\*](#t004fn003){ref-type="table-fn"}       2.81 (0.85--9.22)

Abbreviation: HR, hazard ratio; CI, confidence interval

Adjusted for adjusted for migraine, sex, age, insurance premium, urbanization level, comorbidities and drug used in Cox proportional hazard regression.

\*:\<0.05

\*\*:\<0.01

\*\*\* p\<0.001

Discussion {#sec013}
==========

This nationwide, population-based cohort study demonstrated that migraine in children less than 18 years of age was associated with a 5.30-fold increased risk of narcolepsy. This association was still present after controlling for the effects of potential confounders such as demographic characteristics, comorbidities and concurrent medication uptake. Furthermore, the elevated risk in migraine children was consistently detected in migraine with aura and migraine without aura subtypes, indicating that the study results were robust.

The major strength of the present study was the use of a nationwide population-based database, which enrolled a large sample size and appropriate observation period, thus providing sufficient power to delineate the differences between the two study cohorts. Moreover, a propensity score-matched comparison cohort was used to eliminate possibilities of subject selection bias and the influence of medical care-seeking behavior, thus reinforcing our conclusions that migraine increased the risk of narcolepsy in children. Although not many population-based estimates of narcolepsy in children are available, a European study has indicated an incidence rate of 0.83 out of 100,000 person-years in children between 5 and 19 years of age \[[@pone.0189231.ref011]\]. Here we observe an incidence rate of 2.78 per 100,000 (or 0.0278 per 1,000) person-years in the control cohort \<18 years of age, which is higher than the European study estimate. However, this can be attributed to the fact that our pediatric sample is inclusive of children younger than 5 years old (i.e. lower incidence), or that the baseline properties have been slightly altered after matching with our study sample. Additionally, our study results are further validated since a statistically significant higher hazard ratio of narcolepsy is shown in the migraine children despite our comparatively higher observed incidence in the reference cohort. Occurrence of infectious events (infectious diseases of the upper respiratory tract and influenza) or other illnesses such as hyperactivity and epilepsy which could be capable of triggering narcolepsy onset were also found analogous between our two study cohorts, further confirming the relatively increased risk of narcolepsy attributed to migraine. Still, even after controlled for the effects of other central nervous system conditions like schizophrenia and organic psychosis, affective psychoses, neurotic disorders and others in the analyses, we cannot rule out the fact that these conditions could associate with a narcoleptic syndrome not confounded with idiopathic narcolepsy.

The association between migraine and narcolepsy was inconclusive. In the first hospital-based observational study, migraine showed a 2-fold to 4-fold increase in patients with narcolepsy \[[@pone.0189231.ref002]\]. This data supported their previous findings that half of narcoleptic patients reported migraine in a clinical sample. Nevertheless, a multi-centre case-control study with 96 narcoleptics did not find a significant higher prevalence of narcolepsy with migraine \[[@pone.0189231.ref003]\]. In contrast to these small sample size and case-control study design, our study included a relatively large number of population-based migraine pediatric cases, and a retrospective cohort study design with a sufficiently long follow-up period. Moreover, we focused on pediatric migraine cases, not adults like those addressed in previous studies \[[@pone.0189231.ref002],[@pone.0189231.ref003]\]. Thus, our results support the emerging notion that migraine is associated with the risk of narcolepsy development in children. This association suggests a plausible pathophysiological mechanism that needs to be further investigated.

The exact pathophysiologic mechanisms linking migraine and narcolepsy are unknown. Loss of orexinergic neurons in the hypothalamus has been considered playing a causative role in narcolepsy with cataplexy. There is evidence that dysfunctional hypothalamic activity contributes to narcolepsy as well as altered pain processing via hypothalamic orexinergic neurons, while hypothalamus has been demonstrated in functional and structural brain imaging for migraine \[[@pone.0189231.ref012]--[@pone.0189231.ref015]\]. On other aspects, hypothalamic orexinergic neurons can stimulate neurons in the periaqueductal grey (PAG), locus coeruleus, and the raphe nuclei which inhibit antinociceptive activity in the TNC \[[@pone.0189231.ref013],[@pone.0189231.ref014]\]. Due to the aforementioned relations, it is possible that hypothalamic orexinergic system is both involved in trigeminovascular nociception and narcolepsy developing that predispose some patients to migraine and narcolepsy. Clinical evidence for the role of hypothalamic orexinergic system in the modulation of migraine has not yet clearly identified and warrants further research.

Nevertheless, our results need to be interpreted with caution as several limitations are associated with the present study. First, the diagnoses of migraine and narcolepsy were entirely identified on the basis of ICD-9-CM codes, and therefore, were dependent on the diagnostic accuracy of the NHIRD database. These data may be less accurate than those diagnosed made in a prospective setting through standardized procedures, which may be an inherent weakness for all database research. The NHIA in Taiwan samples the medical charts routinely and has made every effort to verify the accuracy of the diagnoses in the database from every contracted medical institution \[[@pone.0189231.ref016]\]. Ideally, the diagnosis of narcolepsy should be based on the International Classification of Sleep Disorders (ICSD) 2 or 3 criteria which include results from diagnostic tests like multiple sleep latency testing (MSLT) and polysomnography (PSG). However, from our data, a lot of children with narcolepsy may not be diagnosed with the ICSD-2 or -3 diagnostic criteria as majority of data traces back to a period before ICSD-2. A small number of cases are detected even with a nationally representative sample in our study period from 1997 to 2010, suggesting that this disorder did not exhibit much medical attention previously. However, since narcolepsy is a rare disease, with the diagnosis large restricted to neurologists and sleep subspecialists rather than general physicians, its diagnostic accuracy should be failsafe. Furthermore, since many clinicians were unfamiliar with this disorder, narcolepsy remained under-diagnosed, potentially leading to underestimation of the risk of narcolepsy in the migraine cohort. Even so, there still exists the possibility that there are differential diagnoses of narcolepsy in the pediatric population such as delayed circadian phase syndrome or attention deficit hyperactivity disorder. In addition, the diagnosis of migraine was validated previously \[[@pone.0189231.ref017]\]. Nevertheless, a more definite diagnosis of migraine as a primary neurological disorder (versus unspecified migraine; with and without aura) is required to solidify the association between migraine and narcolepsy. Second, headache could potentially be a sign of sleepiness in children. But because we suspected potential confounding exerted by headache, patients with headache (ICD-9-CM: 346.2x; n = 886) were excluded in the selection process, which could lead to underestimation of results. Also, the frequency and severity of narcoleptic or migraine symptoms could not be precisely extracted from ICD codes, and this prevented further analysis. Third, patients in our migraine cohort were considered "active" migraineurs. Patients whose migraine became inactive may have been excluded from the migraine cohort and misclassified as controls. Under these conditions, the risk of developing narcolepsy among patients with migraine might have been underestimated. Fourth, the NHIRD is an administrative database which lacks thorough clinical data, such as disease onset and laboratory results. As a result, our results merely showed the increased associations of narcolepsy in patients with migraine, which may not allow a causal relationship to be established. Finally, most of our study subjects were ethnic Chinese from Taiwan, and the generalizability of our results to other ethnic groups needs to be further confirmed.

Conclusion {#sec014}
==========

This population-based longitudinal study provides evidence that migraine diagnosis is associated with an increased risk of narcolepsy in children. The higher narcolepsy incidence in the pediatric migraine population may indicate a common pathway of pathophysiology relevant to both disorders. Further research is warranted to describe the exact pathophysiological mechanisms linking migraine and narcolepsy.

Public health relevance {#sec015}
=======================

-   The association between migraine and narcolepsy in children has not been explored in a large-scale longitudinal study.

-   As almost one-third of migraine patients become symptomatic before reaching the age of 15, there is an increasing level of attention given on the development of narcolepsy early in life.

-   Using a nationwide population-based study approach, our results support the emerging notion that migraine is associated with the risk of developing narcolepsy in children.

-   This derived association suggests a plausible pathophysiological mechanism that needs to be further investigated.
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